fluorodeoxyuridylate has been researched along with Prostatic Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balaji, KC; Boyacioglu, O; Gmeiner, WH; Jennings-Gee, J; Stuart, CH | 1 |
| Lerner, JL; Menon, RP; Rinaldy, AR; Steiner, MS | 1 |
| Cattaneo-Pangrazzi, RM; Schott, H; Schwendener, RA | 1 |
3 other study(ies) available for fluorodeoxyuridylate and Prostatic Neoplasms
| Article | Year |
|---|---|
The cytotoxic and pro-apoptotic activities of the novel fluoropyrimidine F10 towards prostate cancer cells are enhanced by Zn(2+) -chelation and inhibiting the serine protease Omi/HtrA2.
Topics: Apoptosis; Chelating Agents; Ethylenediamines; Fluorodeoxyuridylate; High-Temperature Requirement A Serine Peptidase 2; Humans; Male; Mitochondrial Proteins; Prostatic Neoplasms; Serine Endopeptidases; Zinc | 2015 |
Role of pHyde novel gene product as an intrinsic factor for apoptotic pathway in prostate cancer.
Topics: Animals; Apoptosis; Cell Cycle; DNA Damage; DNA Repair; Fluorodeoxyuridylate; Gene Expression Regulation, Neoplastic; Humans; Intrinsic Factor; Male; Prostatic Neoplasms; Rats; Tumor Cells, Cultured | 2000 |
The novel heterodinucleoside dimer 5-FdU-NOAC is a potent cytotoxic drug and a p53-independent inducer of apoptosis in the androgen-independent human prostate cancer cell lines PC-3 and DU-145.
Topics: Androgens; Antimetabolites, Antineoplastic; Apoptosis; Biotransformation; Cell Cycle; Cell Division; Cytarabine; Dimerization; Dose-Response Relationship, Drug; Enzyme Inhibitors; Floxuridine; Fluorodeoxyuridylate; Humans; Hydrolysis; Male; Neoplasms, Hormone-Dependent; Phosphodiesterase I; Phosphoric Diester Hydrolases; Prodrugs; Prostatic Neoplasms; Thymidylate Synthase; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2000 |